Last Price$8.511.2%
Market Cap$1,347.5M
P/Revenue LTM
22.7x
5Y avg
32.8x
Biotechnology industry
median
12.0x
Stock quality & Intrinsic value
6/10
0.1% undervalued
Ocular Therapeutix, Inc. P/Revenue LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P/Revenue LTM | 1,778.1x | 130.0x | 115.0x | 67.8x | 86.0x | 77.4x | 116.6x | 13.8x | 4.4x | 6.5x | 22.7x |
Overvalued or undervalued?
Check the intrinsic value for OCUL
and see if it's the right time to invest.
Ocular Therapeutix, Inc. (OCUL) P/Revenue LTM comparison analysis
General
LTM P/Revenue LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Ocular Therapeutix, Inc.OCUL
21.2x
9.0%
11.9%
(303.7%)
Median Peer Set
5.9x
14.8%
(19.3%)
7.5%
argenx SEARGX
15.2x
198.6%
(60.5%)
(24.1%)
Alnylam Pharmaceuticals, Inc.ALNY
13.7x
23.0%
(38.6%)
(12.4%)
Vertex Pharmaceuticals IncorporatedVRTX
11.3x
11.7%
N/A
(4.9%)
BioNTech SEBNTX
8.0x
(77.4%)
(89.7%)
24.4%
Royalty Pharma plcRPRX
6.4x
(3.8%)
(43.7%)
37.9%
Regeneron Pharmaceuticals, Inc.REGN
5.4x
8.3%
10.4%
31.1%
United Therapeutics CorporationUTHR
4.8x
23.6%
25.7%
41.5%
BioMarin Pharmaceutical Inc.BMRN
4.7x
18.0%
139.3%
15.0%
BeiGene, Ltd.BGNE
0.6x
73.7%
467.1%
(35.9%)
Summit Therapeutics Inc.SMMT
N/A
N/A
(68.7%)
N/A
OCUL key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 (100.0%) | 0.8 0.0% | 1.8 126.7% | 1.9 7.8% | 1.9 1.9% | 2.0 3.5% | 4.2 112.4% | 17.4 311.7% | 43.5 150.1% | 51.5 18.3% | 58.4 13.5% | 63.7 9.0% |
| Cost of Goods Sold (COGS) | 0.0 | 10.5 | 0.1 | 0.3 | 0.4 | 0.5 | 0.5 | 2.3 | 2.1 | 4.4 | 4.5 | 5.3 | 5.6 |
% margin | 0.0 30.0% | (10.5) 0.0% | 0.7 88.2% | 1.4 81.8% | 1.4 76.5% | 1.5 76.2% | 1.5 76.6% | 1.9 45.0% | 15.3 88.0% | 39.1 89.9% | 47.0 91.2% | 53.2 91.0% | 58.1 91.2% |
| Operating Expenses | 13.7 | 12.9 | 27.8 | 39.6 | 44.8 | 63.4 | 60.6 | 87.7 | 78.2 | 117.2 | 125.6 | 135.5 | 229.9 |
| Research & Development Expenses (R&D) | 11.5 | 10.5 | 18.9 | 26.6 | 27.1 | 30.9 | 36.9 | 41.1 | 28.7 | 50.1 | 53.5 | 61.1 | 127.6 |
| Selling, General & Administrative Expenses (SG&A) | 2.1 | 2.4 | 8.9 | 13.0 | 17.7 | 32.5 | 23.7 | 46.6 | 49.5 | 67.1 | 72.1 | 74.5 | 102.2 |
% margin | (13.7) (136,710.0%) | (12.9) 0.0% | (27.1) (3,509.6%) | (38.2) (2,182.7%) | (43.3) (2,296.0%) | (61.9) (3,220.1%) | (59.1) (2,970.8%) | (85.8) (2,029.9%) | (62.8) (361.1%) | (78.0) (179.3%) | (78.7) (152.7%) | (82.4) (141.0%) | (171.8) (269.6%) |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.2 | 0.3 | 0.4 | 0.9 | 1.2 | 0.2 | 0.0 | 0.8 | 4.0 | 20.3 |
| Interest Expense | 0.4 | 0.4 | 1.1 | 1.7 | 1.7 | 1.9 | 1.7 | 6.1 | 6.8 | 6.7 | 7.0 | 11.3 | 13.6 |
| Pre-tax Income | (14.1) | (13.3) | (28.6) | (39.7) | (44.7) | (63.4) | (60.0) | (86.4) | (155.6) | (6.6) | (71.0) | (80.7) | (193.5) |
% effective tax rate | 0.3 (2.3%) | 0.5 (3.4%) | 0.1 (0.5%) | 1.0 (2.5%) | 0.8 (1.8%) | 0.3 (0.4%) | (2.3) 3.8% | 3.6 (4.1%) | 4.0 (2.6%) | 4.3 (64.9%) | (7.6) 10.7% | 0.0 0.0% | 0.0 0.0% |
% margin | (14.1) (140,930.0%) | (13.3) 0.0% | (28.6) (3,710.9%) | (39.7) (2,271.3%) | (44.7) (2,369.0%) | (63.4) (3,296.2%) | (57.7) (2,899.1%) | (89.9) (2,127.6%) | (159.6) (917.3%) | (10.8) (24.8%) | (63.4) (123.2%) | (80.7) (138.1%) | (193.5) (303.7%) |
| EPS | (4.77) | (4.51) | (2.69) | (1.71) | (1.80) | (2.20) | (1.51) | (1.99) | (2.63) | (0.14) | (0.83) | (1.09) | (1.22) |
| Diluted EPS | (4.77) | (4.51) | (2.69) | (1.71) | (1.80) | (2.20) | (1.51) | (1.99) | (2.63) | (0.13) | (0.83) | (1.02) | (1.22) |
% margin | (13.3) (133,120.0%) | (12.5) 0.0% | (27.0) (3,495.1%) | (37.3) (2,129.7%) | (42.1) (2,233.3%) | (59.9) (3,113.3%) | (56.0) (2,811.7%) | (77.7) (1,839.2%) | (146.1) (839.5%) | (75.6) (173.7%) | (61.9) (120.2%) | (66.4) (113.6%) | (176.1) (276.4%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Ocular Therapeutix, Inc.'s P/Revenue LTM?
As of today, Microsoft Corp's last 12-month P/Revenue LTM is 22.7x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual P/Revenue LTM for Ocular Therapeutix, Inc. have been 14.8x over the past three years, and 34.5x over the past five years.
2) Is Ocular Therapeutix, Inc.'s P/Revenue LTM Good?
As of today, Ocular Therapeutix, Inc.'s P/Revenue LTM is 22.7x, which is higher than industry median of 12.0x. It indicates that Ocular Therapeutix, Inc.'s P/Revenue LTM is Bad.